Cargando…

Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients

BACKGROUND: Cell lesion and apoptosis with release of cell-free DNA (CFD) in circulation are associated with chronic inflammation of psoriasis. OBJECTIVE: The objective of this study was to determine the CFD concentrations in sera of patients with psoriasis, to assess its relationship with disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Anani, Haneya A A, Tawfeik, Amany M, Maklad, Soheir S, Kamel, Abeer M, El-Said, Enas E, Farag, Asmaa S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293414/
https://www.ncbi.nlm.nih.gov/pubmed/32607312
http://dx.doi.org/10.2147/PTT.S241750
_version_ 1783546298891239424
author Anani, Haneya A A
Tawfeik, Amany M
Maklad, Soheir S
Kamel, Abeer M
El-Said, Enas E
Farag, Asmaa S
author_facet Anani, Haneya A A
Tawfeik, Amany M
Maklad, Soheir S
Kamel, Abeer M
El-Said, Enas E
Farag, Asmaa S
author_sort Anani, Haneya A A
collection PubMed
description BACKGROUND: Cell lesion and apoptosis with release of cell-free DNA (CFD) in circulation are associated with chronic inflammation of psoriasis. OBJECTIVE: The objective of this study was to determine the CFD concentrations in sera of patients with psoriasis, to assess its relationship with disease severity as defined by Psoriasis Area Severity Index (PASI) and other inflammatory biomarkers (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) levels, and to monitor the efficacy of treatment. PATIENTS AND METHODS: Thirty adult patients with different types of psoriasis (25 vulgaris; 10 mild, 15 moderate and 5 erythroderma; severe) were evaluated during the exacerbation phase of the disease, before starting (T0) and after 12 weeks (T12) of treatment with topical therapy for mild cases, narrowband-ultraviolet light B (NB-UVB) for moderate cases and methotrexate for severe cases. Twenty healthy controls were also involved in the study. The concentrations of CFD in sera were measured before and after treatment by quantitative real time PCR (qPCR) using primers of the human β-globin gene. RESULTS: At T0, all patients presented significant higher levels of ESR (P=0.05) and CFD (P=0.001) compared with controls. Highly significant elevations of all parameters were observed in severe disease (erythroderma) compared to mild/moderate disease (vulgaris). Methotrexate treatment induced highly significant reductions in all inflammatory markers including CFD (P= 0.042) while topical and UV irradiation therapies had no effects. CFD concentrations showed positive correlations with both PASI (r=0.422, P=0.020) and ESR (r=0.321, P=0.023) only before the start of treatment. CONCLUSION: The level of circulating CFD could be used to monitor psoriasis severity. However, its level cannot be stated for the treatment, except in severe erythrodermic patients upon successful treatment with methotrexate. We recommend validation of a convenient and accurate DNA assay applied directly to biological samples which does not require prior DNA extraction and amplification.
format Online
Article
Text
id pubmed-7293414
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-72934142020-06-29 Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients Anani, Haneya A A Tawfeik, Amany M Maklad, Soheir S Kamel, Abeer M El-Said, Enas E Farag, Asmaa S Psoriasis (Auckl) Original Research BACKGROUND: Cell lesion and apoptosis with release of cell-free DNA (CFD) in circulation are associated with chronic inflammation of psoriasis. OBJECTIVE: The objective of this study was to determine the CFD concentrations in sera of patients with psoriasis, to assess its relationship with disease severity as defined by Psoriasis Area Severity Index (PASI) and other inflammatory biomarkers (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) levels, and to monitor the efficacy of treatment. PATIENTS AND METHODS: Thirty adult patients with different types of psoriasis (25 vulgaris; 10 mild, 15 moderate and 5 erythroderma; severe) were evaluated during the exacerbation phase of the disease, before starting (T0) and after 12 weeks (T12) of treatment with topical therapy for mild cases, narrowband-ultraviolet light B (NB-UVB) for moderate cases and methotrexate for severe cases. Twenty healthy controls were also involved in the study. The concentrations of CFD in sera were measured before and after treatment by quantitative real time PCR (qPCR) using primers of the human β-globin gene. RESULTS: At T0, all patients presented significant higher levels of ESR (P=0.05) and CFD (P=0.001) compared with controls. Highly significant elevations of all parameters were observed in severe disease (erythroderma) compared to mild/moderate disease (vulgaris). Methotrexate treatment induced highly significant reductions in all inflammatory markers including CFD (P= 0.042) while topical and UV irradiation therapies had no effects. CFD concentrations showed positive correlations with both PASI (r=0.422, P=0.020) and ESR (r=0.321, P=0.023) only before the start of treatment. CONCLUSION: The level of circulating CFD could be used to monitor psoriasis severity. However, its level cannot be stated for the treatment, except in severe erythrodermic patients upon successful treatment with methotrexate. We recommend validation of a convenient and accurate DNA assay applied directly to biological samples which does not require prior DNA extraction and amplification. Dove 2020-05-21 /pmc/articles/PMC7293414/ /pubmed/32607312 http://dx.doi.org/10.2147/PTT.S241750 Text en © 2020 Anani et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Anani, Haneya A A
Tawfeik, Amany M
Maklad, Soheir S
Kamel, Abeer M
El-Said, Enas E
Farag, Asmaa S
Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients
title Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients
title_full Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients
title_fullStr Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients
title_full_unstemmed Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients
title_short Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients
title_sort circulating cell-free dna as inflammatory marker in egyptian psoriasis patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293414/
https://www.ncbi.nlm.nih.gov/pubmed/32607312
http://dx.doi.org/10.2147/PTT.S241750
work_keys_str_mv AT ananihaneyaaa circulatingcellfreednaasinflammatorymarkerinegyptianpsoriasispatients
AT tawfeikamanym circulatingcellfreednaasinflammatorymarkerinegyptianpsoriasispatients
AT makladsoheirs circulatingcellfreednaasinflammatorymarkerinegyptianpsoriasispatients
AT kamelabeerm circulatingcellfreednaasinflammatorymarkerinegyptianpsoriasispatients
AT elsaidenase circulatingcellfreednaasinflammatorymarkerinegyptianpsoriasispatients
AT faragasmaas circulatingcellfreednaasinflammatorymarkerinegyptianpsoriasispatients